Precipio (NASDAQ:PRPO) Stock Rating Lowered by Wall Street Zen

Precipio (NASDAQ:PRPO) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Precipio Trading Down 3.4%

Shares of PRPO stock opened at $26.93 on Friday. The firm has a market cap of $47.13 million, a P/E ratio of -32.84 and a beta of 1.22. Precipio has a 1-year low of $3.90 and a 1-year high of $29.53. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10. The firm’s 50-day simple moving average is $24.68 and its 200-day simple moving average is $22.55.

Institutional Trading of Precipio

A number of institutional investors have recently modified their holdings of PRPO. Susquehanna International Group LLP purchased a new stake in shares of Precipio during the 3rd quarter worth about $194,000. Renaissance Technologies LLC raised its holdings in Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares during the period. Geode Capital Management LLC lifted its position in Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares in the last quarter. Evernest Financial Advisors LLC acquired a new position in Precipio during the third quarter valued at approximately $374,000. Finally, Topline Capital Management LLC purchased a new stake in Precipio during the third quarter worth approximately $1,158,000. Hedge funds and other institutional investors own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.